Swiss Chemical Group Stock Soars 17% Following Dismissal of Billion-Euro Lawsuit

2026-07-31 companies

Muttenz, Friday, 31 July 2026.
Clariant shares surged 17% after a Dutch court dismissed a €1 billion antitrust lawsuit from Shell, removing a critical solvency risk alongside steady second-quarter operating margins.

Market Reaction and Legal Resolution

Shares of Swiss specialty chemicals manufacturer Clariant surged 17.0% on 31 July 2026, marking one of the stock’s sharpest single-session gains in recent memory [5][6]. This significant market movement followed an Amsterdam District Court ruling on 29 July 2026 that dismissed a damages claim brought by Shell regarding a 2020 competition law infringement [6]. The court found no proof that information exchange caused market harm or altered Monthly Contract Price metrics, effectively removing a critical solvency risk where Shell had sought approximately €1 billion in damages [6][1]. Additionally, the court dismissed a separate liability claim from “Stichting Ethylene Claims,” confirming Clariant’s position that it suffered no harm attributable to its conduct [1][6]. While Dow Europe has filed a second lawsuit against Clariant and others, the rejection of claims by Shell and Repsol provides substantial relief to the company [3][4]. The removal of this litigation overhang, combined with a constructive macro backdrop, drove shares to a new 52-week high of 9.21 CHF intraday [6].

Second Quarter Financial Performance

Alongside the legal news, Clariant reported second-quarter 2026 comparable sales rose 0.6% in local currencies to CHF 941.3 million [1]. Reported sales declined 0.3% due to portfolio pruning, though the EBITDA margin before exceptional items increased to 18.2%, up 0.8 percentage points from 17.4% in Q2 2025 [1]. This margin improvement was driven by strong performance in Care Chemicals, which saw a 4.2% sales increase, and Adsorbents & Additives, which grew 5.3% [1]. These gains offset a 13.3% decline in Catalysts sales attributed to ongoing conflict in the Middle East [1]. For the first half of 2026, operating cash flow reached CHF 168.7 million, an improvement from CHF 115.9 million in H1 2025 [1]. Net debt increased to CHF 1,493.1 million from CHF 1,413.9 million at the end of 2025, resulting in a net debt-to-EBITDA ratio of 2.2x [1].

Strategic Outlook and Guidance

Clariant maintains its 2026 guidance for flat sales in local currency and an EBITDA margin of approximately 18% [1]. The company is expanding performance improvement programs by CHF 20 million to reach an annual run-rate of CHF 100 million by 2027, with CHF 90 million of savings targeted for 2026 [1]. Management projects a stronger second half for the Catalysts business as non-Middle East customers resume operations, despite the continued conflict weighing on the segment [1]. As of the H1 2026 reporting period, the company reported 10,107 employees and a Return on Invested Capital of 8.0% [1]. Innovation sales increased to 19.4% for the 12 months ending June 2026, supported by expanded U.S. FDA approval for Licocare’m RBW rice bran wax additives [1]. Investors had been positioning ahead of the earnings report scheduled for 31 July, with the legal clarity further bolstering sentiment [6].

Sources

Antitrust Lawsuits Chemical Sector